🔹The ASCENT trial explores combining afatinib with chemoradiation, with or without surgery, in stage III EGFR-mutant NSCLC.
Results show a 63% response rate to induction TKI, with promising PFS (2.6 years) and OS (5.8 years).

#LungCancer #NSCLC #OncologyResearch Allison Chang

Inició el genocidio del Guerrillero Gustavo Petro y la matasanos Carolina Corcho

Desabastecimiento de medicamentos para tratar el cáncer,

Cabozantinib
Crizotinib
Axitinib
Carmustine
Afatinib
Ciclofosfamia oral
Citarabina
5-Fluor uracilo
Ipilimumab
Asparaginasa
Ondansetron

Interesting review afatinib has an overall advantage over first-generation EGFR-TKIs in the treatment of rare EGFR mutations in lung cancer.
mdpi.com/1718-7729/30/6…

ASCENT is a single arm phase 2 study.

▶️ Who?: Pts w/ stage III EGFR-mutant NSCLC

▶️ What? (see image): afatinib -> cCRT +/- surgery -> afatinib

▶️ Why afatinib?: Trial opened in the pre-osimertinib era.

Osimertinib was approved mid-trial, and so accrual slowed and stopped.

¿Alguien conoce el medicamento afatinib? El cáncer de pulmón se está volviendo una enfermedad crónica al ahora contar con terapias blanco (💊!) que ofrecen sobrevidas mayores de 2️⃣ años. Esto duplica a lo que antes vivían los pacientes solo con quimioterapia: 1️⃣ año.

来那度胺(Lenalidomide) 多发性骨髓瘤
替诺福韦(Tenofovir) 艾滋/乙肝
阿比特胧(Abirapro) 前列腺
阿法替尼(Afatinib) 晚期肺鳞癌
克咄替尼(Crizotinib) 间歇性淋巴瘤
帕哗帕尼(Pazopanib) 晚期肾细胞癌

Great summary of 🦄uncommon EGFR mutations from the EGFR Master Tony Mok

🦄3 most ‘frequent’ uncommon EGFR mutations circled.

🦄Review article summary support afatinib or Osimertinib

Thanks for ESMO - Eur. Oncology Advanced Lung cancer workshop - great morning!

Illustration of dual drug loaded (Afatinib and geftinib) in core-shelled construct of lipid-polymeric nanoparticles in nasopharyngeal cancer therapy
#Phenomcis #tumor #therapy #molecularcancer #cancer
molecular-cancer.biomedcentral.com/articles/10.11…

Dual Inhibition of KRASG12D & Pan-ERBB Is Synergistic in #PDAC
Cancer Research
doi.org/10.1158/0008-5…
👉MRTX1133 upregulates activation of EGFR and HER2
👉MRTX1133 & afatinib synergistic -> longer OS in murine PDAC models
🧐most likely, we need combinations in the clinic
ESMO - Eur. Oncology

ACHILLES study. Afatinib vs chemo for uncommon egfr mutations . Better PFS . Toxicity more with afatinib?? ESMO - Eur. Oncology #ESMO23 OncoAlert

NOW ENROLLING: Champions' new #EGFR Mutant In Vivo Screen featuring 30 unique PDX models including #T790M , #L858R , #C797S , #ex19del , #ex20ins mutations and models resistant to #osimertinib , #erlotinib , #gefitinib , #afatinib , #CPI .
Enroll by August 31st: hubs.li/Q01WYBP80

CLOSING SOON: Champions' new #EGFR Mutant In Vivo Screen featuring 30 unique PDX models including #T790M , #L858R , #C797S , #ex19del , #ex20ins mutations and models resistant to #osimertinib , #erlotinib , #gefitinib , #afatinib , #CPI .
Enroll by August 31st: hubs.li/Q01_0NBr0

...Induction TKI could also help w/ risk stratification. In ASCENT, 2/3 pts w/ apparent cure had outstanding molecular responses to induction tx (pCR + near-pCR) + elected to forego consolid. afatinib.

📢 #NEOLA just opened + will look at induction osi -> cCRT -> maintenance osi.

🔥ACHILLES/TORG1834
🎙️Dr. Satoru Miura
🎯PFS HR 0.422 (95%CI 0.256-0.694). The first phase III compares afatinib and platinum-based chemo in uncommon EGFR mut NSCLC.
✅Phase III RCT
✅Primary: PFS
✅mNSCLC with uncommon EGFR
✅jRCTs 031180175
#ESMO23 #LCSM ESMO - Eur. Oncology OncoAlert

Met NSCLC with CNS involvement.Your treatment of choice-Osimertinib vs Erlotinib+Ramu vs Afatinib Sandip Patel MD Dr Vineet Govinda Gupta Dr Venkata Pradeep babu Koyyala Sewanti Limaye 🇮🇳🇺🇸 Nirmal Raut

Giá thuốc Afatinib có thể thay đổi tùy cơ sở y tế. Bạn nên liên hệ bệnh viện để biết giá chính xác.
Tham Khảo: kingfucoidan.vn/thuoc-Afatinib…
#thuốc_afatinib
#Fucoidan_vàng
#viên_uống_fucoidan
#fucoidan_là_thuốc_gì

Satoru Miura presents Achilles trial, afatinib vs chemo for uncommon EGFR mutation 1st line. Mostly G719X and L861Q but it’s a complex population. Would be interesting to see results of each subgroup separately.

#Afatinib If you need please contact with us on WhatsApp +8801929123476 wa.link/6kfwp3

ACHILLES/ TORG1834: Randomized Phase III trial of Afatinib versus chemotherapy for uncommon sensitizing EGFR mutations.

Improved PFS with Afatinib in first line of treatment: HR 0.44
10.6 months vs 5.7
Known safety profile.

#ESMO23 #LCSM

🎯 Zenocutuzumab in previously treated NRG1+ lung cancer.
✅ ORR 37.2% (N = 78) Median DOR 14.9 months
Included patients previously treated with afatinib.
Good tolerability, most low grade toxicity.
#LCSM #ESMO23